Imagene

Every year, the American Cancer Society publishes its #Cancer Facts & Figures report, providing critical insights into the state of cancer in the U.S. This year’s report highlights concerning trends, including rising cancer rates in younger adults and persistent disparities in outcomes, stressing the urgent need for better diagnostics, early detection, and improved treatment strategies. Increasing access to precision medicine can change lives. Through our collaboration with Tempus AI, we are leveraging digital pathology and AI-powered assays to expand access to NSCLC biomarker testing, ensuring more lung cancer patients receive the right treatment at the right time. AI-powered solutions can predict key molecular statuses within minutes—from the biopsy image alone—helping guide treatment decisions earlier and more efficiently. #CancerResearch #PrecisionMedicine #biomarkers #Pharma #HealthcareInnovation

???? ?????? ?????????????? ???????????????????????????? ???? ???????????????? ????????????: ?????? ???????????????? ???????? ???????????????? A recent comprehensive report by McKinsey explores how AI, advanced analytics, and modern IT infrastructures are reshaping biopharma R&D and clinical trials. As drug development becomes more complex and costly, companies are increasingly looking to technology-driven solutions to improve efficiency, reduce failure rates, and accelerate timelines. We have selected ?????????? ?????? ?????????????????? from the report that highlight the challenges facing clinical trials today and the opportunities AI presents to optimize and accelerate the drug development process: 1. ???????????? ???????????? ?????? ???????????????? ?????????? ????????????????????????: The number of required participants in oncology trials increased from 1.1 million in 2019 to 1.3 million in 2022, reflecting a growing focus on cancer drug development. 2. ?????? ???????????????????? ???? ???????????????? ????????????: Only 6% of U.S. cancer patients participate in clinical trials, with an even lower 4% participation rate at non-NCI (National Cancer Institute) centers, making recruitment a critical bottleneck. 3. ?????????????????? ???????????????????? ???? ???????????????? ????????????: More than 50% of oncology trials in 2022 included biomarker-defined target subpopulations, increasing trial specificity but also making recruitment and trial execution more challenging. 4. ????’?? ???????????? ???? ???????????????? ??????????????????????: AI-driven innovations in trial design, patient recruitment, and predictive analytics are expected to generate over $50 billion annually across drug discovery, research, and clinical development. 5. ???????????? ??&?? ?????????? ?????? ?????????????? ?????????????? ??????????: Inflation-adjusted biopharma R&D spending increased by 44% between 2012 and 2022, yet clinical trial success rates continue to decline, emphasizing the need for efficiency improvements. 6. ????-???????????? ?????????????? ???????????????????? ????????????????????????: AI can identify optimal trial sites and predict enrollment performance, leading to a 10–20% increase in enrollment efficiency. 7. ???????????????????? ???? ?????????????? ???????? ????????????????: Outdated IT infrastructures with fragmented data and siloed systems limit seamless data integration, slowing trial execution and decision-making. These insights highlight the importance of AI, digital transformation, and data-driven strategies in addressing clinical trial challenges, particularly in oncology. For a deeper dive into these findings, we encourage you to read the full report (link in first comment). McKinsey & Company #clinicaltrials #biopharma #AI

NGS + Digital Pathology: Complementary or Competitive? Another big step for AI in oncology diagnostics—Tempus AI and Imagene just announced a partnership to bundle Imagene’s H&E-based molecular biomarker prediction with Tempus’ NGS offerings. The potential? Faster results, stronger AI performance, and a clearer path to algorithm commercialization. Tempus has been building out its own CP capabilities too, with a PLA granted last year for a digital pathology-based MSI algorithm in prostate cancer. And they’re not alone—Guardant Health integrated Lunit Oncology's AI-assisted PD-L1 scoring back in 2023, and PathAI has secured partnerships with labs like Caris Life Sciences and NeoGenomics Laboratories. It’s exciting to see Tempus, Guardant, and others investing in AI-powered CP tools and recognizing the combined value of molecular and histological biomarkers. Right now, these technologies appear to be complementary—but could the relative ease-of-use of DP eventually replace certain molecular tests? Either way, these partnerships reinforce the potential for CP CDx, something I touched on in my previous post. Close collaborations with reference labs will be key to making widespread commercial adoption a reality. DeciBio

We’re excited to announce a collaboration with Imagene focused on launching an AI-powered biomarker prediction panel targeting actionable biomarkers to revolutionize lung cancer diagnostics. Imagene’s innovative lung assay, the first AI-based multi-gene panel for predicting key #NSCLC biomarkers directly from biopsy images within minutes, combined with Tempus’ clinical reach and comprehensive real-world data, is designed to achieve important milestones in precision oncology. Read more: https://lnkd.in/gwAPaEy6

Imagene and Tempus AI are partnering to advance lung cancer diagnostics with an AI-powered biomarker prediction panel. By combining Imagene’s AI-driven lung assay with Tempus’ clinical reach and real-world data, the collaboration aims to provide clinicians with rapid and accurate biomarker predictions for non-small cell lung cancer (NSCLC), improving personalized treatment options. The partnership will refine AI models for enhanced diagnostic accuracy and introduce a bundled solution that integrates molecular testing with AI-driven biomarker analysis. With a shared vision of making AI-powered diagnostics a standard in oncology, Imagene and Tempus are working to transform NSCLC detection and treatment, ultimately improving patient outcomes. Read the full press release on Pathology News: https://lnkd.in/ecrHj_Jw #digitalpathology #pathologynews

We are pleased to announce our collaboration with Tempus AI to advance AI-powered diagnostics for non-small cell lung cancer (NSCLC). This partnership will provide clinicians with rapid and accurate predictions for key NSCLC biomarkers (EGFR, ALK, MET, BRAF, HER2, RET, ROS1) as part of Tempus’ test portfolio, leverage Tempus’ real-world data to ensure cutting-edge accuracy and effectiveness, and deliver a bundled diagnostic solution combining molecular testing and an AI-panel to improve accessibility around the country. ?? Learn more about this collaboration here: https://lnkd.in/ePisE5yG Chris Scotto DiVetta #AIinOncology #PrecisionMedicine #CancerDiagnostics #Biomarkers #NSCLC

AI is redefining healthcare, and nowhere is that more evident than in clinical research and diagnosis. Today on World Cancer Day, I wanted to highlight Imagene, an Israeli startup and standout innovator revolutionizing this. ? Traditionally, cancer treatments followed a one-size-fits-all approach, but with their #AI model, ConvOI - powered by Oracle Cloud Infrastructure - the company is transforming cancer diagnostics. ? AI is being used to analyze biopsy images to rapidly identify unique genetic markers - enabling more precise and personalized treatment. With 1.1 billion parameters trained on over 630,000 tissue images across 40+ organs, this technology is reshaping how doctors approach cancer care. And it’s continuing to learn! ? Collaborating with pioneers like Imagene shows the real-world impact of AI and #cloud. It’s inspiring to see how technology can drive meaningful change, and we’re proud to support innovations that are improving lives. ? Discover more about how AI is transforming healthcare at the upcoming Oracle #CloudWorld Tours across Europe.?https://lnkd.in/gmcAgW6J

This ?????????? ???????????? ?????? 2025, let’s applaud the startups, researchers and healthcare pioneers pushing boundaries to improve cancer outcomes and save lives! Cancer is the leading cause of death worldwide, with nearly 10 million deaths annually. These innovators are facilitating collaboration between tech and healthcare to bring new advancements in cancer care ?? ?? Universal DX and Quest Diagnostics: Colorectal cancer screening ?? Imagene: Real-time biopsy diagnosis ?? Aindra Systems: Cervical cancer screening ?? Current Surgical: Real-time imaging And many more. ?????? ?? ???????????? ???????? ?????????????????? ???????????? ?? ????????????????????! Let’s keep driving innovation, raising awareness, and working towards a world where cancer is no longer a threat. #HealthTech #CancerAwareness #Innovation #Healthcare #WorldCancerDay

The first Compass of 2025 is live! ?? In today’s competitive landscape, clear and compelling company messaging is critical for startup growth. This month’s Compass features a messaging and marketing checklist with expert insights from leaders like Blumberg Capital’s head of marketing Deann Sonoda, marketing leaders from portfolio companies Theator, PerfectScale, Imagene, veteran journalist Alastair Goldfisher, and more.

Benchmarking R&D Success Rates of Leading Pharmaceutical Companies: This new study, published in "Drug Discovery Today", analyzed 2,092 active ingredients across 19,927 clinical trials conducted by 18 leading pharmaceutical companies over 16 years (2006–2022), making it one of the most extensive benchmarks of R&D success rates and a valuable resource for understanding drug development processes. Here is our list of takeaways: 1. Study Scope and Results: This analysis resulted in a total of 274 FDA-approved drugs, with each company achieving an average of 15 approvals over the study period. 2. Likelihood of Approval (LoA): The average LoA from Phase I to FDA approval was 14.3% (range: 8%–23%), which is higher than the commonly referenced 10% benchmark from previous studies but remains too low to support sustainable R&D models. 3. R&D Productivity Challenge: With an average cost of $6.1 billion per approved drug, there is a need for more efficient and cost-effective development processes to ensure long-term sustainability. 4. Shift to External Development: The study shows a paradigm shift in R&D models, with pharmaceutical companies increasingly integrating external development. From 2015 to 2021, 65% of new FDA-approved drugs originated from external sources, reflecting a growing move toward external development to drive pipeline success. 5. Technology Adoption: Emerging tools such as AI, in silico trials, and real-world evidence platforms should be utilized more to potentially increase success rates, reduce costs, and improve overall R&D efficiency. #pharma #ai #healthtech #biopharma #clinicaldevelopment #drugdevelopment #clinicaltrials We do recommend reading the full study - link in the first comment.